Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamCovidVac-M (Sputnik M) Safety and Immunogenicity in Adolescents
NCT06068556Phase 3Unknown
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of Gam-COVID-Vac M in coronavirus disease 2019 (COVID-19). Primary endpoints: Occurrence of adverse events (AE) at 7 days and Occurrence of serious adverse events (SAEs) at 1 year. Status: unknown.
02
Drugs
Gam-COVID-Vac M
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06068556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068556.